The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1379
Fentanyl Nasal Spray (Lazanda) for Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a nasal spray formulation of fentanyl (Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and oral transmucosal use.1

CLINICAL STUDIES — In one study, 114 opioid-tolerant patients (taking ≥60 mg/day of oral morphine or the equivalent) with breakthrough cancer pain were first treated with fentanyl nasal spray (100 – 800 mcg) in an open-label titration phase; 83 patients continued on to a double-blind phase in which 10 breakthrough pain episodes were treated with either fentanyl nasal spray (7 episodes) or placebo (3 episodes). Pain intensity at 30 minutes, the primary endpoint, was significantly less with the active drug.2

In ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fentanyl Nasal Spray (Lazanda) for Pain
Article code: 1379d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian